Rituximab Biosimilars in India — What the Price Gap Actually Means
India was the first country in the world to approve a rituximab biosimilar. Several CDSCO-approved options are now available. The price difference from the originator is substantial and affects the cost of R-CHOP chemotherapy directly.
- India was first — Reditux, approved in 2007, was the world's first rituximab biosimilar — before any European or US equivalent.
- Same target, same regulatory bar — All CDSCO-approved biosimilars must demonstrate comparability to the originator in quality, safety and efficacy before approval is granted.
- Substantial price difference — Published health-economics literature consistently reports Indian biosimilars as substantially cheaper than the originator product.
- Your oncologist decides — Which product is used is a clinical and procurement decision made by your treating team, not a choice you make by reading a brand name.
Medically reviewed by Dr. Naresh Gundu, Medical Oncologist, MBBS (Chalmeda Anand Rao Institute of Medical Sciences, Karimnagar) · DNB Internal Medicine (Sir Gangaram Hospital, New Delhi) · DM Medical Oncology (AIIMS) · Last reviewed September 2026
Several rituximab biosimilars are approved by CDSCO and available in India, including Reditux, which was the world's first rituximab biosimilar when approved in 2007. They target the same CD20 molecule as the originator. The price is substantially lower, which matters directly to the cost of R-CHOP chemotherapy in India.
What is different between originator rituximab and Indian biosimilars?
| Feature | Originator rituximab (MabThera) | Indian biosimilars (e.g. Reditux, Maball) |
|---|---|---|
| Active molecule | Rituximab | Rituximab — same international nonproprietary name |
| Molecular target | CD20 protein on B-lymphocytes | CD20 protein on B-lymphocytes |
| First approved in India | 2001 | 2007 — India was the first country in the world to approve a rituximab biosimilar |
| Regulatory approval | CDSCO-approved original product | CDSCO-approved under India's biosimilar guidelines |
| Manufactured by | Original innovator | Indian pharmaceutical companies |
| Approximate cost tier | Higher — originator pricing | Substantially lower — varies by centre and procurement |
| How it is given | Intravenous infusion in hospital | Intravenous infusion in hospital |
Are biosimilars approved the same way as the original medicine?
A biosimilar must demonstrate to CDSCO that it is comparable to the originator in quality, safety and efficacy before it is approved. This is not the same process as approving a generic tablet. Biological medicines are large, complex molecules produced in living cells, so the comparison involves laboratory characterisation and clinical data.
CDSCO's biosimilar guidelines, updated in 2016, set out exactly what a manufacturer must demonstrate. Approval means the regulator has assessed that evidence. It does not mean the products are chemically identical — no two batches of any biological medicine ever are, including two batches of the originator itself.
The term 'biosimilar' is a regulatory classification, not a marketing claim.
Who rituximab is not suitable for
Rituximab and its biosimilars are not suitable for everyone. Eligibility is decided by an oncologist on the basis of individual clinical assessment, not by the diagnosis alone.
This medicine is generally not used in people who:
- Have active, severe infection — bacterial, viral or fungal — that is not yet controlled
- Have known hypersensitivity to rituximab or to murine (mouse-derived) proteins, which this chimeric antibody contains
- Have tumour cells that do not express the CD20 protein — rituximab has no target without it
- Have active or uncontrolled hepatitis B, because of the risk of serious viral reactivation
- Are pregnant or breastfeeding
- Have been diagnosed with progressive multifocal leukoencephalopathy (PML)
Relative cautions apply in people with severe heart disease and in those who have recently received a live vaccine. Your oncologist will review all of these factors alongside your full history before any treatment decision is made.
What do biosimilar, CD20 and CDSCO mean?
- Biosimilar
- A biological medicine shown to be comparable to an already-approved reference product, following a specific regulatory evaluation. Not the same as a generic — biological molecules are too complex for an exact chemical copy.
- Originator (reference product)
- The original, innovator version of a biological medicine. Other products are compared against it during the regulatory process. For rituximab, the originator sold in India is MabThera.
- CD20
- A protein on the surface of B-lymphocytes, a type of white blood cell. Rituximab binds to CD20 and is only useful if your tumour cells carry this marker. Testing for CD20 is done before treatment is considered.
- CDSCO
- The Central Drugs Standard Control Organisation — India's national drug regulator, equivalent to the US FDA or Europe's EMA. It approves all medicines sold in India, including biosimilars, and publishes the list of approved products.
- Infusion reaction
- A reaction that can occur during or shortly after a rituximab infusion. It is managed in hospital with pre-medications and observation. It can occur with the originator or with any approved biosimilar.
How does the cost of rituximab biosimilars affect R-CHOP treatment?
R-CHOP is a chemotherapy regimen used in certain B-cell lymphomas. The R stands for rituximab, given alongside cyclophosphamide, doxorubicin, vincristine and prednisolone.
Rituximab was historically the most expensive component of this regimen. Multiple health-economics analyses have documented that the availability of CDSCO-approved biosimilars has substantially changed the affordability of R-CHOP in India.
The actual cost at your centre depends on your hospital, city, how many vials your dose requires, and whether your treatment is covered by insurance or a government procurement scheme. Your care team can tell you the specific figure before you start.
What should I ask my care team before starting rituximab?
- Is my tumour confirmed CD20-positive?
- Which product will I receive — originator or biosimilar — and which brand?
- Has hepatitis B screening been done, and if I am positive, is a prophylactic antiviral prescribed?
- What pre-medications and monitoring come with each infusion?
- What is the total cost, and does my insurance or government scheme cover it at this centre?
- What symptoms after an infusion mean I should call you?
Explore 74 more Chemotherapy and Supportive Medicines by Name topics
Generic, Branded & Biosimilar Chemotherapy in India
- Amrit Pharmacy and Subsidised Cancer Drugs
- Biosimilars: Quality, Regulation and Price
- Can You Buy Chemotherapy Drugs Yourself?
- Cold Chain and Drug Storage: Why It Matters
- Counterfeit and Substandard Cancer Drugs
- Generic vs Branded Chemotherapy in India
- How to Check a Chemotherapy Drug Is Approved
- Is Generic Chemotherapy Safe?
- Jan Aushadhi and Government Pharmacy Options
- Patient Assistance Programmes for Cancer Drugs
- Price Control on Cancer Drugs in India
- Questions to Ask About the Drugs You Are Given
- Rituximab Biosimilars in India
- Trastuzumab Biosimilars in India
- Who Chooses the Brand Used for Your Treatment?
- Why the Same Drug Costs Ten Times More
Chemotherapy Drugs by Name
- 5-Fluorouracil (5-FU, Fluracil): What to Expect
- Bleomycin (Bleocip): What to Expect
- Capecitabine (Xeloda, Capegard, Xabine): The Tablet Form
- Carboplatin (Carboplat, Kemocarb): What to Expect
- Chemotherapy Drug Classes Explained
- Chemotherapy Drug Cost by Name
- Chemotherapy Drugs: A Complete Guide by Name
- Cisplatin (Cisplan, Kemoplat): What to Expect
- Cyclophosphamide (Endoxan, Cycloxan): What to Expect
- Cytarabine (Cytosar): What to Expect
- Docetaxel (Taxotere, Docetax, Daxotel): What to Expect
- Doxorubicin (Adrim, Adriamycin): The Red Injection
- Epirubicin: What to Expect
- Etoposide (Etosid, Fytosid): What to Expect
- Gemcitabine (Gemcite, Gemtaz, Oncogem): What to Expect
- Ifosfamide (Holoxan) and Mesna: Why They Go Together
- Irinotecan (Irinotel): What to Expect
- Liposomal Doxorubicin (Lipodox, Caelyx): How It Differs
- Methotrexate (Folitrax): What to Expect
- Mitomycin, Actinomycin and Less Common Agents
- Nab-Paclitaxel (Abraxane, Nabtaxel): How It Differs
- Oxaliplatin (Oxaliplat, Dacotin): What to Expect
- Paclitaxel (Paclitax, Intaxel, Oncotaxel): What to Expect
- Pemetrexed (Alimta, Pemgem, Pemnat): What to Expect
- Reading Your Chemotherapy Chart
- Temozolomide (Temodal, Temoget): The Brain Tumour Tablet
- Vincristine (Cytocristin, Oncovin): What to Expect
- Vinorelbine (Navelbine): What to Expect
- Which Drugs Affect Fertility?
- Which Drugs Affect the Heart, Kidneys or Lungs?
- Which Drugs Cause Hair Loss and Which Do Not?
- Which Drugs Cause Nausea and How Much?
- Which Drugs Cause Neuropathy?
- Why Was This Particular Drug Chosen for Me?
Drug Interactions, TB & Chronic Medicines
HUB — Chemotherapy Drugs by Name
HUB — Generic, Branded and Biosimilar Chemotherapy in India
HUB — Supportive Medicines Used With Chemotherapy
Supportive Medicines by Name
- Acid Blockers (Pantocid, Rantac) During Chemotherapy
- Allopurinol and Tumour Lysis Prevention
- Antibiotics and Antifungals During Chemotherapy
- Aprepitant (Aprecap, Emend) for Delayed Nausea
- Ayurvedic and Herbal Medicines Alongside Chemotherapy
- Cost of Supportive Medicines Across a Course
- Dexamethasone (Dexona) During Chemotherapy
- Emeset and Ondansetron for Chemotherapy Nausea
- Erythropoietin Injections for Low Haemoglobin
- Filgrastim (Grafeel, Neukine) Injections for Low Counts
- Leucovorin: Rescue and Modulation
- Long-Acting Growth Factor (Peg-Grafeel, Neulastim)
- Loperamide (Eldoper) for Chemotherapy Diarrhoea
- Mesna: Protecting the Bladder
- Mouthwashes and Mouth Care Medicines
- Painkillers That Are Safe During Chemotherapy
- Palonosetron and Longer-Acting Anti-Emetics
- The Medicines You Go Home With After Chemotherapy
- Vitamins and Supplements During Chemotherapy
- Why You Must Not Take Paracetamol Before Checking Your Temperature
Frequently asked questions
Is a rituximab biosimilar the same molecule as the original?
They share the same international nonproprietary name, rituximab, and they target the same CD20 molecule. However, no two biological medicines are chemically identical at the molecular level — this is also true of two batches of the same originator product, because they are produced in living cells that introduce small natural variations. CDSCO approval means the regulator has assessed the biosimilar as comparable to the originator in quality, safety and efficacy. 'Comparable' is the precise regulatory term and is more accurate than 'identical.'
Which rituximab biosimilars are approved in India?
Reditux, manufactured by Dr. Reddy's Laboratories, was approved by CDSCO in 2007 — the world's first rituximab biosimilar. Several others have received CDSCO approval in subsequent years, including Maball. The approved list changes as new products are reviewed, so the most reliable current source is the CDSCO product register or the pharmacist at your treating hospital. Your oncology team will use the product their centre carries, and all products available in the hospital pharmacy should have valid CDSCO approval.
How much cheaper is a rituximab biosimilar?
The price difference is substantial and widely reported, but no single figure is reliable here. Prices vary by hospital, city, volume purchased, and whether treatment is covered by a government scheme or insurer. Multiple health-economics analyses have described Indian rituximab biosimilars as available at a fraction of the originator cost. The actual figure at your centre is the only one that matters for your planning, and your oncology team or hospital pharmacist can give you that before treatment starts. Cost alone is never the basis for choosing which product is used.
Can I switch from originator rituximab to a biosimilar during treatment?
This is a clinical decision for your oncologist. ESMO guidance on biological medicines notes that switching between an originator and a biosimilar should involve a clinical discussion about your individual situation — including which cycle you are on and how your disease is responding. In many cases a switch is practicable and many patients transition without difficulty. In some situations your oncologist may have a reason to continue with the product already started. Raise the question with your team if cost or availability is a concern; do not make the switch on your own.
Why does one hospital use a different brand of rituximab from another?
Hospitals in India procure rituximab products through their own pharmacy and supply chains. The brand available at a given centre reflects procurement contracts and formulary decisions made by that institution — not a clinical preference for one approved product over another. All CDSCO-approved products have been assessed against the same regulatory standard. If you want to understand your centre's choice, the hospital pharmacist is the right person to ask.
Does the brand of rituximab affect whether the treatment will work for me?
CDSCO approval means the product has been assessed as comparable to the originator — that is what the regulatory process is designed to establish. Whether rituximab is appropriate for your cancer, and how well treatment is likely to perform, depends on whether your tumour expresses CD20, your cancer type and stage, and your overall fitness. Those factors are far more relevant than which approved brand is used. Your oncologist can explain what your own test results mean for your individual treatment plan.
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Where to find us
Our centres in and around Hyderabad
Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.
Chemotherapy Topics
Browse our complete chemotherapy guide — 1133 pages on side effects, medicines, cost, daily life and care in Hyderabad. Tap any topic to read more.